特奈特普酶
医学
冲程(发动机)
重症监护医学
急性中风
组织纤溶酶原激活剂
溶栓
心脏病学
内科学
机械工程
工程类
心肌梗塞
作者
Lisa R. Sun,Jenny Wilson,Michaela Waak,Amy Kiskaddon,Neil A. Goldenberg,Lori C. Jordan,M L Wolfe Barry
出处
期刊:Stroke
[Ovid Technologies (Wolters Kluwer)]
日期:2023-07-01
卷期号:54 (7): 1950-1953
被引量:3
标识
DOI:10.1161/strokeaha.123.042951
摘要
Tenecteplase is replacing alteplase as the fibrinolytic agent of choice for the acute management of ischemic stroke in many adult stroke centers due to practical and pharmacokinetic advantages in the setting of similar outcomes. Although thrombolytic use is increasing for acute childhood stroke, there is very limited experience with tenecteplase in children for any indication, and importantly, there are no data on safety, dosing, or efficacy of tenecteplase for childhood stroke. Changes in fibrinolytic capacity over childhood, pediatric pharmacological considerations such as age-specific differences in drug clearance and volume of distribution, and practical aspects of drug delivery such as availability in children's hospitals may impact decisions about transitioning from alteplase to tenecteplase for acute pediatric stroke treatment. Pediatric and adult neurologists should prepare institution-specific guidelines and organize prospective data collection.
科研通智能强力驱动
Strongly Powered by AbleSci AI